Courtney J. Mycroft-West
SARS-CoV-2 Spike S1 Receptor Binding Domain undergoes Conformational Change upon Interaction with Low Molecular Weight Heparins
Mycroft-West, Courtney J.; Su, Dunhao; Li, Yong; Guimond, Scott E.; Rudd, Timothy R.; Elli, Stefano; Miller, Gavin; Nunes, Quentin M.; Procter, Patricia; Bisio, Antonella; Forsyth, Nicholas R.; Turnbull, Jeremy E.; Guerrini, Marco; Fernig, David G.; Yates, Edwin A.; Lima, Marcelo A.; Skidmore, Mark A.
Authors
Dunhao Su
Yong Li
Scott Guimond s.e.guimond@keele.ac.uk
Timothy R. Rudd
Stefano Elli
Gavin Miller g.j.miller@keele.ac.uk
Quentin M. Nunes
Patricia Procter
Antonella Bisio
Nicholas R. Forsyth
Jeremy Turnbull j.e.turnbull@keele.ac.uk
Marco Guerrini
David G. Fernig
Edwin A. Yates
Marcelo Andrade De Lima m.andrade.de.lima@keele.ac.uk
Mark Skidmore m.a.skidmore@keele.ac.uk
Abstract
The dependence of the host on the interaction of hundreds of extracellular proteins with the cell surface glycosaminoglycan heparan sulphate (HS) for the regulation of homeostasis is exploited by many microbial pathogens as a means of adherence and invasion. The closely related polysaccharide heparin, the widely used anticoagulant drug, which is structurally similar to HS and is a common experimental proxy, can be expected to mimic the properties of HS. Heparin prevents infection by a range of viruses when added exogenously, including S-associated coronavirus strain HSR1 and inhibits cellular invasion by SARS-CoV-2. We have previously demonstrated that unfractionated heparin binds to the Spike (S1) protein receptor binding domain, induces a conformational change and have reported the structural features of heparin on which this interaction depends. Furthermore, we have demonstrated that enoxaparin, a low molecular weight clinical anticoagulant, also binds the S1 RBD protein and induces conformational change. Here we expand upon these studies, to a wide range of low molecular weight heparins and demonstrate that they induce a variety of conformational changes in the SARS-CoV-2 RBD. These findings may have further implications for the rapid development of a first-line therapeutic by repurposing low molecular weight heparins, as well as for next-generation, tailor-made, GAG-based antiviral agents, against SARS-CoV-2 and other members of the Coronaviridae .
Citation
Mycroft-West, C. J., Su, D., Li, Y., Guimond, S. E., Rudd, T. R., Elli, S., …Skidmore, M. A. SARS-CoV-2 Spike S1 Receptor Binding Domain undergoes Conformational Change upon Interaction with Low Molecular Weight Heparins. arXiv, https://doi.org/10.1101/2020.04.29.068486
Journal Article Type | Article |
---|---|
Online Publication Date | Apr 29, 2020 |
Deposit Date | Jun 16, 2023 |
Journal | arXiv |
Print ISSN | 2331-8422 |
Publisher | Cornell University |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1101/2020.04.29.068486 |
You might also like
Fluorinated nucleosides, nucleotides and sugar nucleotides
(2023)
Journal Article
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search